… exposure targets in ganciclovir therapy remains and to observe underexposure linked with
failure of therapy requires analysis of a wider patient population. Still, ganciclovir remains a …

… have serious consequences for patients. In this study, the outcome of transplant recipients
was assessed in relation to the optimal or suboptimal use of Ganciclovir or Valganciclovir. …

… investigating the relationship between the therapeutic effect of different GCV blood … SOT
recipients, although given the low but significant numbers of transplant recipients failing therapy, …

… treatment included four renal transplant recipients who did not have access to GCV.34 All
patients … a prospective study of LEF in 17 renal transplant recipients with mild CMV disease.35 …

… in lung transplant populations 12. In renal transplant recipients, the use of prophylactic
valGCV demonstrated less GCV resistance when compared to preemptive treatment (6.3% vs. …

… patients approximately 1:3 to 109 adult transplant recipients who developed ganS-CMV
infection during the same time period. Patients … database of SOT recipients with CMV infection/…

… of solid organ and hematopoietic stem cell transplant patients treated with foscarnet for …
Ganciclovir (GCV)-resistant or refractory cytomegalovirus (CMV) infection in transplant recipients …

… The VICTOR study showed comparable efficacy of treatment with intravenous ganciclovir …
in solid organ transplant recipients. Oral therapy is now recommended treatment in clinical …

… The mainstay of treatment and prevention of this infection is ganciclovir and its ester prodrug
… of routine ganciclovir therapeutic drug monitoring (TDM) as a means to optimize treatment. …

… Our results were similar to a study in which 69 transplant patients utilized a standardized
ganciclovir dosing nomogram starting with 5 mg/kg every 12 h adjusted to renal function and …